Announcements Trials
Browse Landscape

Phase

Phase 1 38Phase 2 34Phase 1/2 25Phase 3 3Phase NA 2Phase EARLY_PHASE1 1

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Breast Neoplasms 149Lymphoma 60Precursor Cell Lymphoblastic Leukemia-Lymphoma 47Lymphoma, Large B-Cell, Diffuse 46Leukemia 44Lymphoma, Follicular 39Lymphoma, Non-Hodgkin 35Multiple Myeloma 33Leukemia, Lymphocytic, Chronic, B-Cell 28Leukemia, Myeloid, Acute 25Burkitt Lymphoma 24Neuroblastoma 21Lymphoma, Large-Cell, Immunoblastic 16Hodgkin Disease 16Lymphoma, Mantle-Cell 14Neoplasms 13Triple Negative Breast Neoplasms 12Lymphoma, B-Cell, Marginal Zone 11Sarcoma 10Inflammatory Breast Neoplasms 10Rhabdomyosarcoma 8Recurrence 8Neoplasms, Plasma Cell 8Myelodysplastic Syndromes 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Graft vs Host Disease 8Lymphoma, T-Cell, Peripheral 7Lymphoma, Large-Cell, Anaplastic 7Leukemia, Biphenotypic, Acute 7Lung Neoplasms 6

Interventions

Rituximab 14pirtobrutinib 6ibrutinib 4Vincristine 4Doxorubicin 4Prednisone 3Cytarabine 3Cyclophosphamide 3zanubrutinib 2acalabrutinib 2Methotrexate 2Etoposide 2Bendamustine Hydrochloride 2venetoclax 1tositumomab I-131 1idelalisib 1ibritumomab tiuxetan 1etoposide phosphate 1entecavir 1cirmtuzumab 1axicabtagene ciloleucel 1VAP-cyclo protocol 1Tenofovir 1Radiotherapy 1Melphalan 1Ifosfamide 1Gemcitabine 1Everolimus 1Drug Therapy 1Dexamethasone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Lymphoma, B-Cell × Cyclophosphamide × Clear all
NCT04529772 2026-03-31

ESCALADE

Acerta Pharma BV

Phase 3 Active not recruiting
611 enrolled
Lymphoid

Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT01516580 2026-02-09

Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients

Gustave Roussy, Cancer Campus, Grand Paris

Phase 3 Completed
482 enrolled 1 FDA
Lymphoid

Burkitt Lymphoma, Lymphoma, B-Cell

NCT01855750 2025-02-04

A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

Janssen Research & Development, LLC

Phase 3 Completed
838 enrolled 16 charts
Lymphoid

Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡